ARTICLE | Clinical News

Fortigel meets hypogonadism endpoint

May 9, 2008 1:13 AM UTC

ProStrakan (LSE:PSK) said Fortigel testosterone met the primary endpoint of at least 75% of patients achieving a plasma testosterone reference range of 300-1140 ng/dL at day 90 in the Phase III Fortify trial to treat symptoms of male hypogonadism. The open-label, U.S. trial enrolled 149 patients. ...